Second Opinion

Aducanumab is not just a drug that doesn’t seem to work, but it is an enormously expensive drug but provides false hope to desperate families.

If COVID-19 has taught us anything, one lesson is that we need to rethink allowing promotions for treatments that are overdone, unnecessary, or not proven effective.

For years we have used incentives and disincentives to drive people toward specific behaviors. Is driving toward COVID immunization any different?

Rather than selecting a health care provider based on ability and training, people often rely on demographic data and look for someone they think is like them.

For years pharmaceutical companies have provide gifts and kickbacks to doctors who prescribed their drugs. Medical device manufacturers are now playing the same game and it’s costing all of us.

Asking health care providers a simple question is surprisingly accurate at predicting how long a person has to live and this information can make a big difference in how people chose to live what time they have left.

It is time to re-look at laws intended to protect victims of domestic violence as they have had unintended consequences

Involuntary hospitalization is not an easy decision to make and involves balancing ethical, moral and legal issues while trying to protect a person and society.

It turns out the number of days providers treat common infections with an antibiotic is simply too long.